Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMANCE trial
2025-521319-38-00Phase 2Authorised
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Irinotecan + cetuximab rechallenge with Trifluridine/tipiracil + bevacizumab (2 arms). Primary endpoint: Objective response rate. Planned start Mar 2026; status: authorised.
02
Drugs
irinotecancetuximabtrifluridinetipiracilbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-521319-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521319-38-00.